Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures? - Archive ouverte HAL Access content directly
Journal Articles Frontiers in Medicine Year : 2018

Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures?

(1) , (1)
1

Abstract

Over the past decades, the risk of HBV transfusion-transmission has been steadily reduced through the recruitment of volunteer donors, the selection of donors based on risk-behavior evaluation, the development of increasingly more sensitive hepatitis B antigen (HBsAg) assays, the use of hepatitis B core antibody (anti-HBc) screening in some low-endemic countries, and the recent implementation of HBV nucleic acid testing (NAT). Despite this accumulation of blood safety measures, the desirable zero risk goal has yet to be achieved. The residual risk of HBV transfusion-transmission appears associated with the preseroconversion window period and occult HBV infection characterized by the absence of detectable HBsAg and extremely low levels of HBV DNA. Infected donations tested false-negative with serology and/or NAT still persist and derived blood components were shown to transmit the virus, although rarely. Questions regarding the apparent redundancy of some safety measures prompted debates on how to reduce the cost of HBV blood screening. In particular, accumulating data strongly suggests that HBsAg testing may add little, if any HBV risk reduction value when HBV NAT and anti-HBc screening also apply. Absence or minimal acceptable infectious risk needs to be assessed before considering discontinuing HBsAg. Nevertheless, HBsAg remains essential in high-endemic settings where anti-HBc testing cannot be implemented without compromising blood availability. HBV screening strategy should be decided according to local epidemiology, estimate of the infectious risk, and resources.
Fichier principal
Vignette du fichier
fmed-05-00029.pdf (428.11 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03555713 , version 1 (03-02-2022)

Identifiers

Cite

Daniel Candotti, Syria Laperche. Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures?. Frontiers in Medicine, 2018, 5, pp.29. ⟨10.3389/fmed.2018.00029⟩. ⟨inserm-03555713⟩

Collections

INSERM
12 View
17 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More